Habib, AA, Sacconi, S, Antonini, G, Cortés-Vicente, E, Grosskreutz, J, Mahuwala, ZK, Mantegazza, R, Pascuzzi, RM, Utsugisawa, K, Vissing, J, Vu, T, Wiendl, H, Boehnlein, M, Greve, B, Woltering, F, Bril, V. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. Therapeutic Advances in Neurological Disorders. 2024; 17DOI:10.1177/17562864241273036. PMID:39297052. IF:4.100(Q1/2D).

Domínguez, JMG, Villar, LM, Arrambide, G, Blanco, Y, Calles, MC, Casanova, B, Castillo-Triviño, T, França, LCF, Eichau, S, Pérez, MAH, Landete, L, Lallana, JM, Oreja-Guevara, C, Prieto, JM, Querol, L, Caminero, AB. Relevance of serum neurofilament light chain determination as a biomarker in multiple sclerosis. Consensus of the Spanish Society of Neurology's Study Group on Multiple Sclerosis and Related Neuroimmune Diseases. NEUROLOGIA. 2026; 41(4)DOI:10.1016/j.nrl.2025.501928. PMID:. IF:3.100(Q2/4D).

Kleefeld, F, Gamboa, JT, Pinal-Fernandez, I, Preusse, C, Nelke, C, Goebel, HH, Mensch, A, Mossakowski, A, Miah, MU, Diaz-Manera, J, Torchia, E, Bortolani, S, Hentschel, A, Funke, A, Souvannanorath, S, Authier, FJ, Malfatti, E, Gehrig, J, Mammen, AL, Casal-Dominguez, M, De Winter, J, De Ridder, W, Ruck, T, Schneider, U, Roos, A, Gallardo, E, Tasca, G, Stenzel, W. Brachio-cervical inflammatory myopathy: multilevel clinical, histopathological and multi-omic analyses of a syndrome variably associated with systemic sclerosis. ACTA NEUROPATHOLOGICA. 2026; 151(1)DOI:10.1007/s00401-026-03006-5. PMID:41934478. IF:9.300(Q1/1D).

Cortés-Vicente, E, Guerrero, A, Díaz, C, Martínez, E, Toja-Camba, FJ, Abad, MR, Serra, JM, Trillo, JL, Machín, CM, Gil, A. Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis. ADVANCES IN THERAPY. 2026; 43(4)DOI:10.1007/s12325-026-03490-x. PMID:41591648. IF:4.000(Q1/3D).